23rd Nov 2007 07:01
ABCAM Plc23 November 2007 For immediate release 23 November 2007 ABCAM PLC ("Abcam" or "the Company") Additional Listing and Total Voting Rights Application has been made to AIM for admission of 128,760 Ordinary Shares of 1peach in the Company ("Shares") to trading. These Shares, which will rank paripassu in all respects with the existing shares in issue, have been allottedpursuant to the exercise of options. Admission is expected to become effective on 27th November 2007. For the purposes of the Financial Services Authority's Disclosure andTransparency Rules, the total number of ordinary shares of 1p of Abcam in issueon the date of admission will be 34,985,544 with each share holding one votingright. The above figure may be used by shareholders as the denominator for calculationsby which they will determine if they are required to notify their interest in,or a change to their interest in the Company, under the Disclosure andTransparency Rules. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerJeffrey Iliffe, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7776 1500James Black Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts and aJapanese office in Tokyo. Abcam was admitted to AIM in November 2005 and tradesunder the ticker symbol ABC. The Company produces and distributes its own andthird party produced antibodies to academic and commercial users throughout theworld with product information provided and ordering available through theCompany's website, www.abcam.com. The antibodies are sold under the Abcam brandname. The Company's vision is to build the largest online antibody resource inthe world while also ensuring that the antibodies are of high quality andcommercially viable. Abcam now has an online catalogue of approximately 40,000products, most of which are antibodies, from over 200 suppliers supported byup-to-date and detailed technical data sheets, which are created by the Company.The Company currently employs 140 staff in its three operating companies. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
ABC.L